帕比司他可诱导CD38上调，并增强达雷妥尤单抗的抗骨髓瘤疗效。 - Suppr

Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab.

作者信息

García-Guerrero Estefanía, Gogishvili Tea, Danhof Sophia, Schreder Martin, Pallaud Celine, Pérez-Simón Jose Antonio, Einsele Hermann, Hudecek Michael

机构信息

Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/Consejo Superior de Investigaciones Científicas/Universidad de Sevilla, Seville, Spain; and.

出版信息

Blood. 2017 Jun 22;129(25):3386-3388. doi: 10.1182/blood-2017-03-770776. Epub 2017 May 5.

DOI:10.1182/blood-2017-03-770776

PMID:28476749

Abstract

摘要

相似文献

Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab.

Blood. 2017 Jun 22;129(25):3386-3388. doi: 10.1182/blood-2017-03-770776. Epub 2017 May 5.

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.

Leukemia. 2021 Jan;35(1):201-214. doi: 10.1038/s41375-020-0840-y. Epub 2020 Apr 29.

Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands.

Int J Mol Sci. 2024 Apr 26;25(9):4718. doi: 10.3390/ijms25094718.

Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA.

Br J Haematol. 2019 Jun;185(5):969-974. doi: 10.1111/bjh.15673. Epub 2018 Nov 26.

Molecular dynamics of targeting CD38 in multiple myeloma.

Br J Haematol. 2021 May;193(3):581-591. doi: 10.1111/bjh.17329. Epub 2021 Feb 11.

Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.

Oncotarget. 2016 Nov 29;7(48):79064-79075. doi: 10.18632/oncotarget.12594.

Panobinostat for the Treatment of Multiple Myeloma.

Clin Cancer Res. 2015 Nov 1;21(21):4767-73. doi: 10.1158/1078-0432.CCR-15-0530. Epub 2015 Sep 11.

Deacetylase inhibitors: an advance in myeloma therapy?

Expert Rev Hematol. 2017 Mar;10(3):229-237. doi: 10.1080/17474086.2017.1280388. Epub 2017 Feb 1.

Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.

Med Sci Monit. 2017 Oct 29;23:5150-5157. doi: 10.12659/msm.904232.

New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.

Curr Pharm Des. 2013;19(4):734-44.

引用本文的文献

Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma.

Blood Neoplasia. 2024 Jun 10;1(3):100025. doi: 10.1016/j.bneo.2024.100025. eCollection 2024 Sep.

CD38 in the pathobiology of cutaneous T-cell lymphoma and the potential for combination therapeutic intervention.

Leukemia. 2025 May;39(5):1146-1156. doi: 10.1038/s41375-025-02551-4. Epub 2025 Mar 8.

Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects.

Front Immunol. 2025 Feb 12;16:1519300. doi: 10.3389/fimmu.2025.1519300. eCollection 2025.

Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands.

Int J Mol Sci. 2024 Apr 26;25(9):4718. doi: 10.3390/ijms25094718.

Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives.

Exp Hematol Oncol. 2024 Apr 23;13(1):45. doi: 10.1186/s40164-024-00507-5.

Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma.

Nat Commun. 2024 Feb 14;15(1):1367. doi: 10.1038/s41467-024-45561-z.

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma.

Leukemia. 2023 Sep;37(9):1925-1928. doi: 10.1038/s41375-023-01983-0. Epub 2023 Aug 2.

Cytokine receptor IL27RA is an NF-κB-responsive gene involved in CD38 upregulation in multiple myeloma.

Blood Adv. 2023 Aug 8;7(15):3874-3890. doi: 10.1182/bloodadvances.2022009044.

CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD-Lowering Agents.

Antioxidants (Basel). 2023 Feb 15;12(2):494. doi: 10.3390/antiox12020494.

Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance.

Front Oncol. 2022 Oct 27;12:1020011. doi: 10.3389/fonc.2022.1020011. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献